Associations of task technology fit and perceived usefulness with responsible generative AI use among university students - Nature

Indocyanine green may be highly sensitive in the identification of ovarian cancer metastases, though with low specificity. IntroductionOvarian cancer is the second most common malignancy of the female genital tract in the United States, according to the American College of Obstetricians and Gynecologists, 2017.1 In terms of mortality, it ranked eighth worldwide in 2013 and fifth in Poland in 2019 among all cancers.2,3 The high mortality rate associated with ovarian cancer is mainly due to its late diagnosis. At the time of diagnosis, two-thirds of patients present with intraperitoneal dissemination, corresponding to International Federation of Gynecology and Obstetrics (FIGO) stage III or IV.4 The most important prognostic indicator in patients with advanced-stage ovarian cancer is the volume of residual disease after cytoreductive surgery.4 The primary treatment approach remains debulking surgery. The goal of this procedure is to achieve complete cytoreduction.

The investigational factor XI (FXI) monoclonal antibodies amrecibart and cenvacibart demonstrated successful anticoagulation with a favorable safety profile in preclinical and phase 1 clinical studies, representing a novel treatment strategy for patients with thrombosis. The results were published in Blood by Dan Chalothorn, PhD, of Regeneron Pharmaceuticals, and colleagues. The research team first compared the mechanisms and coagulation effects of amrecibart and cenvacibart with other FXI-targeted monoclonal antibodies in both human and nonhuman primate plasma using an in vitro functional clotting assay.1Targeting the Intrinsic PathwayWith unique FXI/FXIa-binding mechanisms, amrecibart and cenvacibart address an unmet need for novel treatments with a favorable risk-benefit profile because current standard-of-care anticoagulants carry a high risk for bleeding. Cenvacibart and amrecibart block FXI activity by targeting the catalytic domain and the apple 2 domain of FXI/FXIa, respectively. Although standard-of-care anticoagulants target the extrinsic coagulation pathway, these monoclonal antibodies specifically target the intrinsic coagulation pathway.

Google kicked off 2026 with the addition of Personal Intelligence to Gemini, allowing its AI to pull in more of your data to formulate answers. It started as a paid feature but eventually came to all Gemini users. However, this feature wasn’t available in the car until now. Google is rolling out Personal Intelligence to Android Auto and Google Built-in, and it is still, thankfully, an optional feature. As Google points out, a generative AI’s outputs are better “when it knows the world and knows you,” which is correct in an uncomfortable sort of way. The more context you can provide to a model, the better the output will be at the end of the token shuffle. Since Google has so much of your data already, it sees Personal Intelligence as a differentiator versus other AI systems. You don’t have to provide the AI context because it already has it from apps like Gmail and Calendar.